Tumor subtypes and survival in male breast cancer
Purpose Male breast cancer is an uncommon disease, and population-based information regarding prognostic factors is limited. Most cases are hormone receptor (HR) positive; however, the association of tumor subtype with overall survival (OS) and breast cancer-specific survival (BCSS) is unclear. Meth...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2021-08, Vol.188 (3), p.695-702 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 702 |
|---|---|
| container_issue | 3 |
| container_start_page | 695 |
| container_title | Breast cancer research and treatment |
| container_volume | 188 |
| creator | Leone, Julieta Freedman, Rachel A. Lin, Nancy U. Tolaney, Sara M. Vallejo, Carlos T. Leone, Bernardo A. Winer, Eric P. Leone, José Pablo |
| description | Purpose
Male breast cancer is an uncommon disease, and population-based information regarding prognostic factors is limited. Most cases are hormone receptor (HR) positive; however, the association of tumor subtype with overall survival (OS) and breast cancer-specific survival (BCSS) is unclear.
Methods
Using SEER data, we identified men with invasive breast cancer between 2010 and 2017 with known HR and HER2 status. We examined tumor subtypes by patient characteristics and performed multivariate Cox proportional hazards analyses to determine the associations of each variable with OS and BCSS.
Results
We included 2389 men with a median follow-up of 43 months (IQR 19–68). Median age was 66 years. Tumor subtype distribution was 84.1% HR+/HER2−, 12.7% HR+/HER2+ , 0.8% HR−/HER2+, and 2.3% triple-negative (TN). In univariate analysis, OS at 5 years was 76.5% for HR+/HER2−, 65.1% for HR+/HER2+ , 84.2% for HR-/HER2+, and 48.1% for TN (
p
|
| doi_str_mv | 10.1007/s10549-021-06182-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2506291425</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A668168895</galeid><sourcerecordid>A668168895</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-ca79627403fa51c8f6bbe263fab36257c90716bd2749a9adc5d379a38fbd7e103</originalsourceid><addsrcrecordid>eNp9kV1LwzAYhYMobk7_gBdSEMSb6pukTZrLMfyCgTfzOqRpqpU2mUk72L83c34jkovwJs85vIeD0DGGCwzALwOGPBMpEJwCwwVJ1ztojHNOU04w30VjwIynrAA2QgchPAOA4CD20YhSzoHibIzwYuicT8JQ9uulCYmyVRz8qlmpNmls0qnWJKU3KvSJVlYbf4j2atUGc_R-T9DD9dVidpvO72_uZtN5qjNO-1QrLhjhGdBa5VgXNStLQ1icSspIzrUAjllZRUQooSqdV5QLRYu6rLjBQCfofOu79O5lMKGXXRO0aVtljRuCJDkwInBG8oie_kKf3eBt3C5SmRBMAONf1GPMJBtbu94rvTGVU8YKzIpCbLwu_qDiqUzXaGdN3cT3H4Kzb4Ino9r-Kbh26Btnw0-QbEHtXQje1HLpm075tcQgN4XKbaEyFirfCpXrKDp5jzaUnak-JR8NRoBugRC_7KPxX9n_sX0Fh8-n4A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2549969067</pqid></control><display><type>article</type><title>Tumor subtypes and survival in male breast cancer</title><source>SpringerNature Complete Journals</source><creator>Leone, Julieta ; Freedman, Rachel A. ; Lin, Nancy U. ; Tolaney, Sara M. ; Vallejo, Carlos T. ; Leone, Bernardo A. ; Winer, Eric P. ; Leone, José Pablo</creator><creatorcontrib>Leone, Julieta ; Freedman, Rachel A. ; Lin, Nancy U. ; Tolaney, Sara M. ; Vallejo, Carlos T. ; Leone, Bernardo A. ; Winer, Eric P. ; Leone, José Pablo</creatorcontrib><description>Purpose
Male breast cancer is an uncommon disease, and population-based information regarding prognostic factors is limited. Most cases are hormone receptor (HR) positive; however, the association of tumor subtype with overall survival (OS) and breast cancer-specific survival (BCSS) is unclear.
Methods
Using SEER data, we identified men with invasive breast cancer between 2010 and 2017 with known HR and HER2 status. We examined tumor subtypes by patient characteristics and performed multivariate Cox proportional hazards analyses to determine the associations of each variable with OS and BCSS.
Results
We included 2389 men with a median follow-up of 43 months (IQR 19–68). Median age was 66 years. Tumor subtype distribution was 84.1% HR+/HER2−, 12.7% HR+/HER2+ , 0.8% HR−/HER2+, and 2.3% triple-negative (TN). In univariate analysis, OS at 5 years was 76.5% for HR+/HER2−, 65.1% for HR+/HER2+ , 84.2% for HR-/HER2+, and 48.1% for TN (
p
< 0.0001). Of all subtypes, TN had the worst BCSS (
p
< 0.0001). Stage, tumor subtype and race were significantly associated with OS and BCSS in multivariate analysis. Adjusted Cox hazard ratios for OS by tumor subtype with HR+/HER2− as reference were 1.55 for HR+/HER2+ (p = 0.001), 1.1 for HR−/HER2+ (
p
= 0.888), and 3.59 for TN (
p
< 0.001).
Conclusion
We observed significant differences in survival outcomes by tumor subtype. Poor outcomes among men with HER2+ and TN disease suggest possible under-treatment, aggressive tumor biology, and/or more advanced disease at presentation. Studies to better understand the inferior survival for men with these subtypes are warranted and will likely require international collaboration.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-021-06182-y</identifier><identifier>PMID: 33770314</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Analysis ; Breast cancer ; Cancer research ; Epidemiology ; ErbB-2 protein ; Invasiveness ; Medical prognosis ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Mens health ; Multivariate analysis ; Oncology ; Prognosis ; Survival</subject><ispartof>Breast cancer research and treatment, 2021-08, Vol.188 (3), p.695-702</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>COPYRIGHT 2021 Springer</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-ca79627403fa51c8f6bbe263fab36257c90716bd2749a9adc5d379a38fbd7e103</citedby><cites>FETCH-LOGICAL-c473t-ca79627403fa51c8f6bbe263fab36257c90716bd2749a9adc5d379a38fbd7e103</cites><orcidid>0000-0002-8537-652X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-021-06182-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-021-06182-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33770314$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leone, Julieta</creatorcontrib><creatorcontrib>Freedman, Rachel A.</creatorcontrib><creatorcontrib>Lin, Nancy U.</creatorcontrib><creatorcontrib>Tolaney, Sara M.</creatorcontrib><creatorcontrib>Vallejo, Carlos T.</creatorcontrib><creatorcontrib>Leone, Bernardo A.</creatorcontrib><creatorcontrib>Winer, Eric P.</creatorcontrib><creatorcontrib>Leone, José Pablo</creatorcontrib><title>Tumor subtypes and survival in male breast cancer</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
Male breast cancer is an uncommon disease, and population-based information regarding prognostic factors is limited. Most cases are hormone receptor (HR) positive; however, the association of tumor subtype with overall survival (OS) and breast cancer-specific survival (BCSS) is unclear.
Methods
Using SEER data, we identified men with invasive breast cancer between 2010 and 2017 with known HR and HER2 status. We examined tumor subtypes by patient characteristics and performed multivariate Cox proportional hazards analyses to determine the associations of each variable with OS and BCSS.
Results
We included 2389 men with a median follow-up of 43 months (IQR 19–68). Median age was 66 years. Tumor subtype distribution was 84.1% HR+/HER2−, 12.7% HR+/HER2+ , 0.8% HR−/HER2+, and 2.3% triple-negative (TN). In univariate analysis, OS at 5 years was 76.5% for HR+/HER2−, 65.1% for HR+/HER2+ , 84.2% for HR-/HER2+, and 48.1% for TN (
p
< 0.0001). Of all subtypes, TN had the worst BCSS (
p
< 0.0001). Stage, tumor subtype and race were significantly associated with OS and BCSS in multivariate analysis. Adjusted Cox hazard ratios for OS by tumor subtype with HR+/HER2− as reference were 1.55 for HR+/HER2+ (p = 0.001), 1.1 for HR−/HER2+ (
p
= 0.888), and 3.59 for TN (
p
< 0.001).
Conclusion
We observed significant differences in survival outcomes by tumor subtype. Poor outcomes among men with HER2+ and TN disease suggest possible under-treatment, aggressive tumor biology, and/or more advanced disease at presentation. Studies to better understand the inferior survival for men with these subtypes are warranted and will likely require international collaboration.</description><subject>Analysis</subject><subject>Breast cancer</subject><subject>Cancer research</subject><subject>Epidemiology</subject><subject>ErbB-2 protein</subject><subject>Invasiveness</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Mens health</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Survival</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kV1LwzAYhYMobk7_gBdSEMSb6pukTZrLMfyCgTfzOqRpqpU2mUk72L83c34jkovwJs85vIeD0DGGCwzALwOGPBMpEJwCwwVJ1ztojHNOU04w30VjwIynrAA2QgchPAOA4CD20YhSzoHibIzwYuicT8JQ9uulCYmyVRz8qlmpNmls0qnWJKU3KvSJVlYbf4j2atUGc_R-T9DD9dVidpvO72_uZtN5qjNO-1QrLhjhGdBa5VgXNStLQ1icSspIzrUAjllZRUQooSqdV5QLRYu6rLjBQCfofOu79O5lMKGXXRO0aVtljRuCJDkwInBG8oie_kKf3eBt3C5SmRBMAONf1GPMJBtbu94rvTGVU8YKzIpCbLwu_qDiqUzXaGdN3cT3H4Kzb4Ino9r-Kbh26Btnw0-QbEHtXQje1HLpm075tcQgN4XKbaEyFirfCpXrKDp5jzaUnak-JR8NRoBugRC_7KPxX9n_sX0Fh8-n4A</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Leone, Julieta</creator><creator>Freedman, Rachel A.</creator><creator>Lin, Nancy U.</creator><creator>Tolaney, Sara M.</creator><creator>Vallejo, Carlos T.</creator><creator>Leone, Bernardo A.</creator><creator>Winer, Eric P.</creator><creator>Leone, José Pablo</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8537-652X</orcidid></search><sort><creationdate>20210801</creationdate><title>Tumor subtypes and survival in male breast cancer</title><author>Leone, Julieta ; Freedman, Rachel A. ; Lin, Nancy U. ; Tolaney, Sara M. ; Vallejo, Carlos T. ; Leone, Bernardo A. ; Winer, Eric P. ; Leone, José Pablo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-ca79627403fa51c8f6bbe263fab36257c90716bd2749a9adc5d379a38fbd7e103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analysis</topic><topic>Breast cancer</topic><topic>Cancer research</topic><topic>Epidemiology</topic><topic>ErbB-2 protein</topic><topic>Invasiveness</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Mens health</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leone, Julieta</creatorcontrib><creatorcontrib>Freedman, Rachel A.</creatorcontrib><creatorcontrib>Lin, Nancy U.</creatorcontrib><creatorcontrib>Tolaney, Sara M.</creatorcontrib><creatorcontrib>Vallejo, Carlos T.</creatorcontrib><creatorcontrib>Leone, Bernardo A.</creatorcontrib><creatorcontrib>Winer, Eric P.</creatorcontrib><creatorcontrib>Leone, José Pablo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leone, Julieta</au><au>Freedman, Rachel A.</au><au>Lin, Nancy U.</au><au>Tolaney, Sara M.</au><au>Vallejo, Carlos T.</au><au>Leone, Bernardo A.</au><au>Winer, Eric P.</au><au>Leone, José Pablo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor subtypes and survival in male breast cancer</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>188</volume><issue>3</issue><spage>695</spage><epage>702</epage><pages>695-702</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
Male breast cancer is an uncommon disease, and population-based information regarding prognostic factors is limited. Most cases are hormone receptor (HR) positive; however, the association of tumor subtype with overall survival (OS) and breast cancer-specific survival (BCSS) is unclear.
Methods
Using SEER data, we identified men with invasive breast cancer between 2010 and 2017 with known HR and HER2 status. We examined tumor subtypes by patient characteristics and performed multivariate Cox proportional hazards analyses to determine the associations of each variable with OS and BCSS.
Results
We included 2389 men with a median follow-up of 43 months (IQR 19–68). Median age was 66 years. Tumor subtype distribution was 84.1% HR+/HER2−, 12.7% HR+/HER2+ , 0.8% HR−/HER2+, and 2.3% triple-negative (TN). In univariate analysis, OS at 5 years was 76.5% for HR+/HER2−, 65.1% for HR+/HER2+ , 84.2% for HR-/HER2+, and 48.1% for TN (
p
< 0.0001). Of all subtypes, TN had the worst BCSS (
p
< 0.0001). Stage, tumor subtype and race were significantly associated with OS and BCSS in multivariate analysis. Adjusted Cox hazard ratios for OS by tumor subtype with HR+/HER2− as reference were 1.55 for HR+/HER2+ (p = 0.001), 1.1 for HR−/HER2+ (
p
= 0.888), and 3.59 for TN (
p
< 0.001).
Conclusion
We observed significant differences in survival outcomes by tumor subtype. Poor outcomes among men with HER2+ and TN disease suggest possible under-treatment, aggressive tumor biology, and/or more advanced disease at presentation. Studies to better understand the inferior survival for men with these subtypes are warranted and will likely require international collaboration.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33770314</pmid><doi>10.1007/s10549-021-06182-y</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8537-652X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2021-08, Vol.188 (3), p.695-702 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2506291425 |
| source | SpringerNature Complete Journals |
| subjects | Analysis Breast cancer Cancer research Epidemiology ErbB-2 protein Invasiveness Medical prognosis Medical research Medicine Medicine & Public Health Medicine, Experimental Mens health Multivariate analysis Oncology Prognosis Survival |
| title | Tumor subtypes and survival in male breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A10%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20subtypes%20and%20survival%20in%20male%20breast%20cancer&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Leone,%20Julieta&rft.date=2021-08-01&rft.volume=188&rft.issue=3&rft.spage=695&rft.epage=702&rft.pages=695-702&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-021-06182-y&rft_dat=%3Cgale_proqu%3EA668168895%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2549969067&rft_id=info:pmid/33770314&rft_galeid=A668168895&rfr_iscdi=true |